We discuss recent published research on how a vitamin B3 derivative reduces new skin cancer risk, as well as other types of UV damage.
* Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.
My Personal Biomedical Research Feed – Ralph Turchiano, CEO Alchepharma
We discuss recent published research on how a vitamin B3 derivative reduces new skin cancer risk, as well as other types of UV damage.
* Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.
Subscribe now to keep reading and get access to the full archive.